Minerva Imaging, a leading radiopharmaceutical platform, today announced the appointment of Patrik Dahlen as new Chair of the Board.

Minerva Imaging is a science-driven CRO and CDMO specialising in targeted radioligand therapies, a fast-emerging and transformative field within cancer therapeutics. The company delivers an integrated platform for pharmaceutical and biotechnology partners and continues to expand its capabilities as global demand for radiopharmaceutical development increases.

Patrik Dahlen brings extensive international leadership experience from life science, medtech and diagnostics. He has served as CEO of several public and private companies, including Dako, Immunodiagnostics Systems (IDS), NeuroSearch and SSI Diagnostica, and currently holds multiple Chair and Board roles within Nordic life science and diagnostics companies. He has significant experience in strategy development and scaling science-driven organisations across Europe and the United States.

“Minerva represents a rare combination of strong scientific roots and an integrated radiopharmaceutical platform. I very much look forward to working with the board and management team as the company continues to develop its capabilities and international partnerships,” said Patrik Dahlen.

“We are very pleased to welcome Patrik as Chair. His background from building and leading advanced diagnostics businesses is highly relevant for Minerva and strengthens the board as we continue to advance our integrated research-to-clinic offering,” said Carsten H. Nielsen, CEO and founder of Minerva Imaging.

Nordic Capital has been a partner to Minerva since 2025 and intends to support the company’s growth journey and ambition to build a global market-leading radiopharmaceutical platform.

“As the radiopharmaceutical field continues to evolve rapidly, strong governance, industry expertise and international experience become increasingly important. Patrik brings all three, and Nordic Capital looks forward to continuing to support Minerva’s long-term development together with the founders and management team,” said Jonas Agnblad, Partner and Co-Head of Nordic Capital Evolution advisory.

Patrik Dahlen

About Minerva Imaging 

Minerva Imaging is a fully integrated CRO and CDMO specialized in targeted radionuclide therapies. The company focusses on the use of advanced models within oncology, cardiovascular diseases and in vivo molecular imaging for translational research and drug development. Minerva Imaging engages with its clients to understand their scientific questions and discuss how its methods and capabilities can provide answers. The facility located in Denmark offers best–in–industry fully integrated radiopharmaceutical research, drug development and manufacturing services. Minerva’s competences are built on over 25 years of research within oncology and molecular imaging performed at the University of Copenhagen and Rigshospitalet, the National University Hospital of Denmark. Follow Minerva Imaging on LinkedIn for the latest news updates or visit www.minervaimaging.com for more information.